透析医が透析患者になってわかった　しっかり透析のヒケツ　改訂2版

出版社： メディカ出版
著者：
発行日： 2014-07-01
分野： 臨床医学：内科  >  腎臓
ISBN： 9784840448895
電子書籍版： 2014-09-01 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

3,850 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,850 円(税込)

購入する

商品紹介

「しっかり透析して、しっかり食べる」方針で診療と自らの透析を行う著者が、元気で長生きするための透析を解説した好評書の改訂版。エビデンスなどの情報も刷新し、腎臓の働きから至適透析まで、よりわかりやすく丁寧に解説する。透析室にかかわるすべてのスタッフ必読。

目次

  • 透析医が透析患者になってわかった　しっかり透析のヒケツ
    改訂2版

    ―目次―

    【1章 腎臓の働き、慢性腎不全、透析の原理】
    （1）腎機能の働きと体液
    （2）慢性腎不全でみられる症状や検査における異常
    （3）血液透析の実際
    （4）血液透析の原理と透析条件
    （5）透析の器材と生体適合性
    （6）透析液について

    【2章 人工腎臓としての血液透析】
    （1）血液透析の体への影響と急性合併症
    （2）人工腎臓（血液透析）と生体の腎臓の比較
    （3）体にやさしい透析とは
    （4）ヘモダイアリシスプロダクトという考え方
    （5）患者が元気で長生きするために大切なこと

    【3章 しっかり透析の基礎知識】
    （1）尿毒素除去の評価の仕方
    （2）透析時間について考える
    （3）血液流量と透析液流量から透析効率を考える
    （4）ダイアライザと濾過型治療から透析効率を考える
    （5）透析量とその周辺

    【4章 水分と塩分のコントロール】
    （1）基礎体重とその調整の仕方
    （2）基礎体重を決めるための検査
    （3）透析間体重増加と積極的な水分管理
    （4）のどの渇きと塩分のコントロール
    （5）除水と循環血液量の変化
    （6）血液透析と血圧運動

    【5章 しっかり食べて、しっかり透析する】
    （1）透析生活と栄養・食事
    （2）栄養状態の評価
    （3）栄養障害と生命予後、その治療

    【6章 バスキュラーアクセスに気を配る】
    （1）バスキュラーアクセスとその使い方
    （2）バスキュラーアクセスの観察と合併症

    【7章 患者さん本位の至適透析をめざして】
    （1）透析導入期の注意点
    （2）透析療法と医療経済
    （3）至適透析をめざして

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 腎臓の働き、慢性腎不全、透析の原理

P.1 掲載の参考文献
1) 黒川清. 腎臓病学. 第2版. 尾前照雄ほか編. 医学書院, 1989, 1-11.
 
2) Chatoth, DK. "Elements of renal structure and function". Cecil essentials of medicine. 5th ed. Carpenter, CC. et al., eds. W.B. Saunders, 2001, 223-31.
 
3) 長谷川昭. "腎臓および尿路 (体液を含む)". 血液浄化療法ハンドブック. 改訂第3版. 透析療法合同専門委員会編. 協同医書出版社, 2004, 23-38.
 
4) 河原克雅. "体液の調節". 標準生理学. 第6版. 本郷利憲ほか編. 医学書院, 2005, 760-5.
 
5) 日本腎臓学会. "CKDの診断の進め方". CKD診療ガイド. 日本腎臓学会編, 2007, 36-9.
 
6) 荒井純子. "慢性腎不全, 尿毒症とは : 定義, 原因, 病期分類, 重症度分類". 腎不全. 阿部正和ほか編. 金原出版, 1986, 74-81.
 
7) 透析療法合同専門委員会. "慢性腎不全の病態生理". 血液浄化療法ハンドブック. 第2版. 透析療法合同専門委員会編. 協同医書出版社, 1998, 331-403.
 
8) Skorecki, K. "Chronic renal failure". Harrison's principles of internal medicine. 15th ed. Braunwald, E. et al., eds. McGraw-Hill, 2001, 1551-62.
 
9) Shaver, MJ. "Chronic renal failure". Cecil essentials of medicine. 5th ed. Carpenter, CC. et al., eds. W. B. Saunders, 2001, 291-300.
 
10) Bergstrom, J. "Uremic toxins". Replacement of renal function by dialysis. Drucker, W. et al., eds. Martinus Nijhoff Publishers, 1983, 354-90.
 
11) Vanholder, R. Uremic toxicity : Present state of art. Int J Artif Organ. 24, 2001, 695-725.
 
12) Vanholder, R. Review on uremic toxins : Classification, concentration, and interindividual variability. Kidney Int. 63, 2003, 1934-43.
PubMed
13) Vanholder, R. New insight in uremic toxins. Kidney Int. 63 (suppl 84), 2003, s6-s10.
 
14) Horl, WH. Are new toxins appearing on the horizon? Contrib Nephrol. 133, 2001, 28-41.
PubMed
15) Massy, SG. Parathyroid hormone and the uremic manifestations. Contrib Nephrol. 20, 1980, 84-91.
 
16) Massy, SG. Current status of the role of parathyroid hormone in uremic toxicity. Contrib Nephrol. 49, 1985, 1-11.
 
17) Feinfeld, DA. The role of parathyroid hormone as a uremic toxin : Current concepts. Semin Dial. 5, 1992, 48-53.
 
18) Bro, S. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis. 30, 1997, 606-20.
PubMed
19) Baab, AL. The middle molecule hypothesis in perspective. Am J Kidney Dis. 1, 1981, 46-50.
 
20) Vanholder, R. Uremic toxicity : The middle molecule hypothesis revisited. Semin Nephrol. 14, 1994, 205-18.
PubMed
21) Vanholder, R. The middle-molecule hypothesis 30 years after : Lost and rediscovered in the universe of uremic toxicity. 21, 2008, 146-60.
PubMed
22) 日本腎臓学会. "治療のまとめ". CKD診療ガイド. 日本腎臓学会編. 2007, 表紙裏.
 
23) 川口良人. 透析導入ガイドラインの策定と追跡調査に関する研究. 平成4年度厚生科学研究・腎不全医療研究事業報告書. 厚生省, 1993, 156-64.
 
24) 日本透析医学会. 維持血液透析ガイドライン : 血液透析導入. 透析会誌. 46, 2013, 1107-55.
 
25) 三浦直文. 血液透析の実際. Clinical Engineering. 13, 2002, 281-6.
 
26) 阿部富彌. 生体の腎臓とは似ても似つかない人工腎臓. Clinical Engineering. 5, 1994, 235-40.
 
27) 峰島三千男. "血液浄化療法の工学的基礎知識". 血液浄化療法ハンドブック. 改訂第3版. 透析療法合同専門委員会編. 協同医書出版社, 2004, 103-29.
 
28) 山下明泰. 血液透析・血液濾過の原理 : 分子拡散と限外濾過. Clinical Engeneering. 19, 2008, 353-8.
 
29) 峰島三千男. Qダイアライザの血液と透析液はなぜ同じ向きに流してはいけないのでしょうか? Clinical Engineering. 15, 2004, 870-1.
 
30) Ronco, C. Backfiltration : A controversial issue in modern dialysis. Int J Artif Organs. 11, 1988, 69-74.
PubMed
31) Leypoldt, JK. Measurement of backfiltration rates during hemodialysis with highly permeable membranes. Blood Purif. 9, 1991, 74-84.
PubMed
32) Leypoldt, JK. Net ultrafiltration may not eliminate backfiltration during hemodialysis with highly permeable membranes. Artif Organs. 15, 1991, 164-70.
 
33) 山下明泰. "逆濾過・逆拡散". 血液透析スタッフのための新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学社, 1998, 230-46.
 
34) 峰島三千男. "血液透析". 血液浄化療法ハンドブック. 改訂第3版. 透析療法合同専門委員会編. 協同医書出版社, 2004, 149-53.
 
35) 福田誠. ダイアライザの機能と構造. Clinical Engineering. 13, 2002, 287-92.
 
36) 石崎直人. 透析器. 臨牀透析. 23, 2007, 793-810.
 
37) 峰島三千男. クリアランスの定義. 臨牀透析. 14, 1998, 91-5.
 
38) 峰島三千男. クリアランスの算出法. 臨牀透析. 14, 1998, 227-31.
 
39) 峰島三千男. ふるい係数の定義. 臨牀透析. 14, 1998, 1499-503.
 
40) 峰島三千男. ふるい係数に及ぼす血流量, ろ液流量の影響. 臨牀透析. 14, 1998, 1611-4.
 
41) 峰島三千男. 真のふるい係数と反射係数. 臨牀透析. 14, 1998, 1725-9.
 
42) 峰島三千男. 血液の限外濾過特性. 臨牀透析. 14, 1998, 1861-4.
 
43) 峰島三千男. 限外濾過に及ぼす影響因子. 臨牀透析. 14, 1998, 1981-4.
 
44) 峰島三千男. 限外濾過率と濾過係数. 臨牀透析. 15, 1999, 129-32.
 
45) 佐藤威. 各種の血液浄化法の機能と適応 : 血液浄化器の性能評価法と機能分類. 透析会誌. 29, 1996, 1231-45.
 
46) 川西秀樹. 新たな透析液水質基準と血液浄化器の機能分類. 透析会誌. 38, 2005, 149-54.
 
47) 篠田俊雄. 血液浄化器の性能評価基準に見合った機能分類, 透析液水質基準の再検討. HDF療法 '07. 日本HDF研究会編. 東京医学社, 2007, 64-7.
 
48) 川西秀樹. 血液浄化器 (中空糸型) の機能分類2013. 透析会誌. 46, 2013, 501-6.
 
49) 酒井良忠. "PMMA". 新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学社, 1998, 54-63.
 
50) 吉田政司. "PEPA". 新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学社, 1998, 94-103.
 
51) 内藤秀宗. "膜吸着". 新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学社, 1998, 210-25.
 
52) 田島直人. 透析膜の高分子化合物吸着能. 日本臨牀. 62 (suppl 5), 2004, 78-82.
 
53) 安藤義孝. 透析膜の物質除去性能. 日本臨牀. 62 (suppl 5), 2004, 72-7.
 
54) 甲田豊. "臨床症状の改善". 新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学社, 1998, 158-70.
 
55) 金成泰. "ハイパフォーマンスダイアライザーでは改善されない症状". 新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学, 1998, 171-82.
 
56) The EBPG expert group on haemodialysis. Biocompatibility. Nephrol Dial Transplant. 17 (suppl 7), 2002, 32-44.
 
57) 峰島三千男. 生体適合性の工学面からみた展開. 臨牀透析. 20, 2004, 503-10.
 
58) 小田稔. 透析機器に関する生体適合性の基本的な考え方. 臨牀透析. 20, 2004, 511-6.
 
59) 上松一誠. 合成高分子膜と生体適合性. 日本臨牀. 62 (suppl 5), 2004, 37-40.
 
60) 甲田豊. "HDFと生体適合性". HDF療法ハンドブック. 日本HDF研究会編. 南江堂, 2000, 99-107.
 
61) Hakim, RM. Clinical implications of biocompatibility in blood purification membranes. Nephrol Dial Transplant. 15 (suppl 2), 2000, s16-s20.
 
62) Jofre, R. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol. 17 (suppl 3), 2006, s274-s280.
 
63) 櫻井健治. HP膜の生体適合性についての検討. 腎と透析. 57 (suppl ハイパフォーマンスメンブレン '05), 2005, 137-42.
 
64) 申曽洙. PS膜透析器との関連が危惧される病態について. 腎と透析. 63 (suppl ハイパフォーマンスメンブレン '07), 2007, 275-9.
 
65) 大橋篤. 血液回路から溶出する内分泌攪乱物質Di- (2-ethylhexyl) phthalateの溶出実態とハイパフォーマンス膜による除去についての検討. 透析会誌. 32, 1999, 1291-7.
 
66) Yamasaki, H. Determination of bisphenol A in effluents of hemodialyzer. Nephron. 88, 2001, 376-8.
PubMed
67) 牧尾健司. PS膜ダイアライザーの充填液と溶出物の分析. 腎と透析. 55 (suppl ハイパフォーマンスメンブレン '03), 2003, 222-7.
 
68) Kjellstrand, CM. Beyond ultrapure hemodialysis : A necessary and achievable goal. Hemodial Int. 11, 2007, s39-s48.
 
69) 田岡正宏. プライミングの適正量の検討と全自動コンソールの性能評価. 腎と透析. 51 (HDF '01), 2001, 177-81.
 
70) Caruana, RJ. Dialyzer hypersensitivity syndrome : Possible role of allergy to ethylene oxide. Report of 4 cases and review of the literature. Am J Nephrol. 5, 1985, 271-4.
PubMed
71) Tielemans, C. Anapylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int. 38, 1990, 982-4.
 
72) Bergman, H. "Complications during hemodialysis". Handbook of dialysis. 3rd ed. Daugirdas, JT. et al., eds. Lippincott Williams & Wilkins, 2001, 148-68.
 
73) 海津嘉蔵. 体外循環時の凝固・線溶・血小板機能. 日本臨牀. 62 (suppl 5), 2004, 46-9.
 
74) 瓜生康平. 抗凝固剤の種類と使用法. 日本臨牀. 62 (suppl 5), 2004, 163-7.
 
75) 信楽園病院腎センター. "抗凝固薬". 透析療法マニュアル. 第6版. 鈴木正司監. 日本メディカルセンター, 2005, 175-81.
 
76) Bohler, J. "Thrombogenesis and anticoagulation in patients undergoing chronic hemodialysis". Replacement of renal function by dialysis. 5th ed. Horl, WH. et al., eds. Kluwer academic publishers, 2004, 259-71.
 
77) 鈴木正司. 血液を水で浄める. Clinical Engineering. 5, 1994, 247-53.
 
78) 松金隆夫. 血液透析液. 臨牀透析. 23, 2007, 995-1003.
 
79) Palmer, BF. Individualizing the dialysate in the hemodialysis patient. Semin Dial. 14, 2001, 41-9.
PubMed
80) 斎藤明. 透析液概論 : 種類と問題点. 日本臨牀. 62 (suppl 5), 2004, 109-16.
 
81) 山田敏生. 処方透析液. 日本臨牀. 62 (suppl 5), 2004, 117-20.
 
82) Locatelli, F. Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Trasplant. 19, 2004, 785-96.
 
83) Sam, R. Composition and clinical use of hemodialysates. Hemodial Int. 10, 2006, 15-28.
PubMed
84) Flanigan, MJ. Role of sodium in hemodialysis. Kidney Int. 58 (suppl 76), 2000, s72-s78.
 
85) 木村玄次郎. "透析患者のNaバランス". ワンポイントノートで学ぶ透析療法の基本. 東京医学社, 1993, 71-83.
 
86) Mann, H. Sodium modeling. Kidney Int. 58 (suppl 76), 2000, s79-s88.
 
87) Stiller, S. A critical review of sodium profiling for hemodialysis. Semin Dial. 14, 2001, 337-47.
PubMed
88) Keen, ML. The association of the sodium"setpoint"to interdialytic weight gain and blood pressure in hemodialysis patients. Int J Artif Organ. 30, 2007, 971-9.
 
89) 外畑巌. "電解質と不整脈". 心電図学. 石川恭三編. 南山堂, 1986, 1107-16.
 
90) Rachoin, JS. How should dialysis fluid be individualized for the chronic hemodialysis patients? Potassium. Semin Dial. 21, 2008, 223-5.
PubMed
91) Toussaint, N. Review of dialysate calcium concentration in hemodialysis. Hemodial Int. 10, 2006, 326-37.
PubMed
92) Mclntyre, CW. Calcium balance during hemodialysis. Semin Dial. 21, 2008, 38-42.
 
93) 重松隆. Ca濃度2.75mEq/L透析剤K-FT1の臨床的検討 : 多施設共同第III相比較臨床試験. 新薬と臨床. 61, 2012, 368-87.
Medical*Online
94) Mehrotra, R. Metabolic acidosis in maintenance dialysis patients : Clinical considerations. Kidney Int. 64 (suppl 88), 2003, s13-s25.
 
95) 斎藤明. 酢酸フリー透析剤SZ-D21 多施設共同比較臨床試験 (第III相試験). 診療と新薬. 44, 2007, 260-78.
 
96) Lowrie, EG. Death risk in hemodialysis patients : The predictive value of commonly measured variables and an evaluation of death differences between facilities. Am J Kidney Dis. 15, 1999, 458-82.
 
97) Bommer, J. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 44, 2004, 661-71.
PubMed
98) Wu, DY. Association between serum bicarbonate and death in hemodialysis patients : Is it better to be acidic or alkalotic? Clin J Am Soc Nephrol. 1, 2006, 70-8.
PubMed
99) 日本透析医学会. 図説わが国の慢性透析療法の現況 (2009年12月31日現在). 2010, 86-9.
 
100) Uribarri, J. Association of acidosis and nutritional parameters in hemodialysis patients. Am J Kidney Dis. 34, 1999, 493-9.
PubMed
101) Uribarri, J. Moderate metabolic acidosis and its effects on nutritional parameters in hemodialysis patients. Clin Nephrol. 48, 1997, 238-40.
PubMed
102) Kirschbaum, B. Effect of high bicarbonate hemodialysis on ionized calcium and risk of metastatic calcification. Clinica Chimica Acta. 343, 2004, 231-6.
 
103) Tentori, F. Association of dialysate bicarbonate concentration with mortality in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 62, 2013, 738-46.
PubMed
104) Uribiarri, J. How should dialysis fluid be individualized for the chronic hemodialysis patients? Bicatbonate. Semin Dial. 21, 2008, 221-3.
 
105) Vinay, P. Acetate metabolism during hemodialysis : Metabolic considerations. Am J Nephrol. 7, 1987, 337-54.
PubMed
106) Mann, NK. Acetate-free biofiltration : State of art. Contrib Nephrol. 108, 1994, 87-93.
 
107) 久野勉. Biofiltration. 日本臨牀. 62 (suppl 5), 2004, 172-7.
 
108) Tomo, T. Biocompatibility of dialysis fluid for online HDF. Contrib Nephrol. 168, 2011, 889-98.
 
109) Kuragano, T. Acetate free citrate-containing dialysate increase intact-PTH and BAP levels in the patietnts with low intact-PTH. BMC Nephrol. 14, 2013, 18.
 
110) 岩本ひとみ. 透析液清浄化理論. 日本臨牀. 62 (suppl 5), 2004, 121-5.
 
111) 内野順司. 水処理の実際. 日本臨牀. 62 (suppl 5), 2004, 126-32.
 
112) 信楽園病院腎センター. "水処理装置". 透析療法マニュアル. 第6版. 鈴木正司監. 日本メディカルセンター, 2005, 143-52.
 
113) EBPG expert group on haemodialysis. Dialysis fluid purity. Nephrol Dial Transplant. 17 (suppl 7), 2002, 45-62.
 
114) 酒井良忠. "ISO 23500および関連基準案の審議動向". HDF療法 '07. 日本HDF研究会編. 東京医学社, 2007, 8-11.
 
115) 川西秀樹. "透析液水質基準の再検討". HDF療法 '07. 日本HDF研究会編. 東京医学社, 2007, 72-5.
 
116) 峰島三千男. 血液浄化器の性能と水質管理の関係. Clinical Engineering. 19, 2008, 886-91.
 
117) Canaud, B. On-line haemodiafiltration : State of art. Nephrol Dial Transplant. 13 (suppl 59), 1998, s3-s11.
 
118) 金成泰. "大量液置換HDF : とくにon-line HDFの臨床効果". HDF療法ハンドブック. 日本HDF研究会編. 南江堂, 2000, 134-40.
 
119) Passlick-Deetjen, J. On-line hemodiafiltration. Gold standard or top therapy. Contrib Nephrol. 137, 2002, 201-11.
PubMed
120) Lonnemann, G. Chronic inflammation in hemodialysis : The role of contaminated dialysate. Blood Purif. 18, 2000, 214-23.
PubMed
121) Ward, R. Ultrapure dialysate. Semin Dial. 17, 2004, 489-97.
PubMed
122) Masakane, I. Review : Clinical usefulness of ultrapure dialysate-Recent evidence and perspectives. Ther Apher Dial. 10, 2006, 348-54.
PubMed
123) Ledebo, I. Clinical benefits of ultrapure dialysis fluid for hemodialysis. Hemodial Int. 11, 2007, s12-s17.
 

2章 人工腎臓としての血液透析

P.37 掲載の参考文献
1) 谷口興一. 循環動態. 日本臨牀. 49 (suppl血液浄化療法上巻), 1991, 69-80.
 
2) 田部井薫. 呼吸・循環動態. 日本臨牀. 62 (suppl 5), 2004, 41-5.
 
3) Selby, NM. The acute cardiac effects of dialysis. Semin Dial. 20, 2007, 220-8.
PubMed
4) Converse Jr. RL. Paradoxical withdrawal if reflex vasoconstriction as a cause of hemodialysis induced hypotension. J Clin Invest. 90, 1992, 1657-65.
 
5) Combe, C. Granulocyte activation and adhesion molecules during hemodialysis with cupropahne and a highflux biocompatible membrane. Am J Kidney Dis. 24, 1994, 437-42.
 
6) Pergola, PE. Body temperature during hemodialysis in long-term patients : Is it time to change dialysate temperature prescription? Am J Kidney Dis. 44, 2004, 155-65.
PubMed
7) Maggiore, Q. Studies on hemodialysis hyperthermia. Blood Purif. 2, 1984, 125-9.
 
8) Maggiore, Q. Vascular stability and heat in dialysis patients. Contrib Nephrol. 41, 1984, 398-402.
PubMed
9) Maggiore, Q. Thermal balance and dialysis hypotension. Int J Artif Organ. 9, 1995, 518-25.
 
10) Pizzarelli, F. From cold dialysis to isothermic dialysis : A twenty-five year voyage. Nephrol Dial Transplant. 22, 2007, 1007-12.
PubMed
11) Rosales, LM. Isothermic hemodialysis and ultrafiltration. Am J Kidney Dis. 36, 2000, 353-61.
PubMed
12) Passlick-Deetjen, J. Why thermosensing? A primer on thermoregulation. Nephrol Dial Transplant. 20, 2005, 1784-9.
PubMed
13) Selby, NM. A systematic review of the clinical effects of reducing dialysate fluid temperature. Nephrol Dial Transplant. 21, 2006, 1883-98.
PubMed
14) Schneditz, D. Keep your temper : How to avoid heat accumulation in haemodialysis. Nephrol Dial Transplant. 16, 2001, 7-9.
PubMed
15) Santoro, A. Thermal balance in convective therapies. Nephrol Dial Transplant. 18 (suppl 7), 2003, 41-5.
 
16) Schneditz, D. The (wind) chill factor controlled. Am J Kidney Int. 40, 2002, 426-8.
 
17) Kaufman, AM. Effects of controlled blood cooling on hemodynamic stability and urea kinetics during highefficiency hemodialysis. J Am Soc Nephrol. 9, 1998, 877-83.
PubMed
18) 信楽園病院腎センター. "血液浄化療法の生体への影響". 透析療法マニュアル. 第6版. 鈴木正司監. 日本メディカルセンター, 2005, 86-98.
 
19) 渡辺泉. 不均衡症候群. 日本臨牀. 62 (suppl 6), 2004, 262-6.
 
20) 椿原美治. "透析中の症状と対策". 新標準透析療法. 飯田喜俊ほか編. 中外医学社, 2001, 269-85.
 
21) 酒井清孝. 血液透析による生体腎機能の代行とその限界. Clinical Engineering. 13, 2002, 273-80.
 
22) 金成泰. "ハイパフォーマンスダイアライザーでは改善されない症状". 新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学社, 1998, 171-82.
 
23) Gotch, FA. A mechanistic analysis of the National Cooperative Dialysis Study. Kidney Int. 28, 1985, 526-34.
PubMed
24) 木村玄次郎. Urea kineticsとKt/V. 臨床医. 21, 1995, 222-6.
 
25) 金田浩. "あとがき". 21世紀の慢性透析治療法を革命しよう. 東京医学社, 2001, 101-4.
 
26) Casino, FG. The equivalent renal urea clearance : A new oarameter to assess dialysis dose. Nephrol Dial Transplant. 11, 1996, 1574-81.
 
27) Clark, WR. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol. 10, 1999, 601-9.
PubMed
28) Kjellstrand, C. Daily hemodialysis : History and revival of a superior dialysis method. ASAIO J. 44, 1998, 115-22.
 
29) Traeger, J. Short daily hemodialysis : A four-year experience. Dial Transplant. 30, 2001, 76-86.
 
30) Williams, AW. Early clinical, quality-of-life, and biochemical changes of "daily hemodialysis". (6 dialysis per week). Am J Kidney Dis. 43, 2004, 90-102.
PubMed
31) Punal, J. Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis : A systematic review. Nephrol Dial Transplant. 23, 2008, 2634-46.
PubMed
32) The FNH trial group. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 363, 2010, 2287-300.
 
33) Pierratos, A. Nocturnal home haemodialysis : Three-year experience. J Am Soc Nephrol. 9, 1998, 859-68.
PubMed
34) Charra, B. Survival as an index of adequacy of dialysis. Kidney Int. 41, 1992, 1286-91.
PubMed
35) 金田浩. "われわれの行っている標準透析 (5時間透析) と長時間透析 (6時間以上の透析) の比較". 21世紀の慢性透析治療法を革命しよう. 東京医学社, 2001, 23-40.
 
36) Alloatti, S. Long nocturnal dialysis. Blood purif. 20, 2002, 525-30.
PubMed
37) Lacson, E. Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. J Am Soc Nephrol. 23, 2012, 687-95.
PubMed
38) Scribner, BH. The hemodialysis product (HDP) : A better index of dialysis adequacy than Kt/V. Dial Transplant. 31, 2002, 13-5.
 
39) Kjellstrand, C. Daily hemodialysis : Dialysis for the next century. Adv Ren Replace Ther. 5, 1998, 267-74.
PubMed
40) Lindsay, RM. The London, Ontario, daily/nocturnal hemodialysis study. Semin Dial. 17, 2004, 85-91.
PubMed
41) 日本透析医学会. わが国の慢性透析療法の現況 (2011年12月31日現在). 2012, 表1721.
 
42) Pierratos, A. Daily (quotidian) nocturnal home hemodialysis : Nine years later. Hemodial int. 8, 2004, 45-50.
PubMed
43) 日本透析医学会. わが国の慢性透析療法の現況 (2011年12月31日現在). 2012, 表1.
 
44) 日本透析医学会. わが国の慢性透析療法の現況 (2011年12月31日現在). 2012, 表1720.
 
45) 渡邊有三. 在宅 (家庭) 血液透析についての提言. 透析会誌. 31, 1998, 959-65.
 
46) Bleyer, AJ. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 55, 1999, 1533-9.
 
47) 原田欣子. 血液透析患者の透析曜日と入院リスクの関係. 腎と透析. 51 (suppl HDF療法 '01), 2001, 102-5.
 
48) Karnik, JA. Cardiac arrest and sudden death in dialysis units. Kidney Int. 60, 2001, 350-7.
PubMed
49) Bkeyer, AJ. Characteristics of sudden death in hemodialysis patients. Kidney Int. 69, 2006, 2268-73.
 
50) Genovesi, S. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol Dial Transplant. 24, 2009, 2529-36.
 
51) Foley, RN. Long interdialytic interval and mortality among patinets receiving hemodialysis. N Engl J Med. 365, 2011, 1099-107.
 
52) Zhang, H. Dialysis outcomes and analysis of practice patterns suggests the dialysis schedule affects day-ofweek mortality. Kidney Int. 81, 2012, 1108-15.
PubMed
53) Scribner, BH. Why thrice weekly dialysis? Hemodial Int. 8, 2004, 188-92.
PubMed
54) Kjellstrand, C. "Unphysiology" of dialysis : A major cause of dialysis side effects? Kidney Int. 7 (suppl 2), 1975, s30-s34.
 
55) 中井滋. わが国の慢性透析療法の現況 (2005年12月31日現在). 透析会誌. 40, 2007, 1-30.
 
56) 日本透析医学会. わが国の慢性透析療法の現況 (2008年12月31日現在). 2009, 表1196・表1227・表1399・表1567・表1843・表1999・表2386・表2554.
 
57) 日本透析医学会. わが国の慢性透析療法の現況 (1997年12月31日現在). 1998, 372-412.
 
58) 日本透析医学会. わが国の慢性透析療法の現況 (1998年12月31日現在). 1999, 611-45.
 
59) 日本透析医学会. わが国の慢性透析療法の現況 (1999年12月31日現在). 2000, 959-89.
 
60) 日本透析医学会. わが国の慢性透析療法の現況 (2000年12月31日現在). 2001, 477-510.
 

3章 しっかり透析の基礎知識

P.63 掲載の参考文献
1) Barri, YMH. "Approach to the patient with renal disease". Cecil essentials of medicine. 5th ed. Carpenter, CC. et al., eds. W. B. Saunders, 2001, 232-7.
 
2) 峰島三千男. クリアランスの定義. 臨牀透析. 14, 1998, 91-5.
 
3) 峰島三千男. クリアランスの算出法. 臨牀透析. 14, 1998, 227-31.
 
4) 峰島三千男. "血液浄化療法の工学的基礎知識". 血液浄化療法ハンドブック. 改訂第3版. 透析療法合同専門委員会編. 協同医書出版社, 2004, 103-29.
 
5) 山下明泰. 除去量と除去率 (1). 臨牀透析. 15, 1999, 1571-5.
 
6) 山下明泰. 除去量と除去率 (2). 臨牀透析. 15, 1999, 1737-42.
 
7) 山下明泰. コンパートメントモデル (I) : データ解析. 臨牀透析. 15, 1999, 1301-5.
 
8) 山下明泰. コンパートメントモデル (II) : 処方への応用. 臨牀透析. 15, 1999, 1483-7.
 
9) Gotch, FA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int. 28, 1985, 526-34.
PubMed
10) Daugirdas, JT. Overestimation of hemodialysis dose depends on dialysis efficiency by regional blood flowbut not by conventional two pool urea kinetic analysis. ASAIO J. 41, 1995, M719-24.
 
11) 日本透析医学会. わが国の慢性透析療法の現況 (2001年12月31日現在). 2002, 559.
 
12) Shinzato, T. Survival in long-term haemodialysis patients : Results from the annual survey of the Japanese society for dialysis therapy. Nephrol Dial Transplant. 12, 1997, 884-8.
PubMed
13) Held, PJ. Mortality and duration of hemodialysis treatment. JAMA. 265, 1991, 871-5.
PubMed
14) Saran, R. Longer treatment time and slower ultrafiltration in hemodialysis : Association with reduced mortality in the DOPPS. Kidney Int. 69, 2006, 1222-8.
PubMed
15) Marshall, MR. Association of hemodialysis dose and session length with mortality risuk in Australian and New Zealand patients. Kidney Int. 69, 2006, 1229-36.
PubMed
16) Brunelli, SM. Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Kidney Int. 77, 2010, 630-6.
PubMed
17) Tentori, F. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis : results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 27, 2012, 4180-8.
PubMed
18) Flythe, JE. Shorter length dialysis sessions are associated with increased mortality, independent of body weight. Kidney Int. 83, 2012, 104-13.
PubMed
19) 日本透析医学会. 維持血液透析ガイドライン : 血液透析処方. 透析会誌. 46, 2013, 587-632.
 
20) Tattersall, J. EBPG guideline on dialysis strategies. Nephrol Dial Transplant. 22 (suppl 2), 2007, ii5-ii21.
 
21) Charra, B. Survival as an index of adequacy of dialysis. Kidney Int. 41, 1992, 1286-91.
PubMed
22) 日本透析医学会. わが国の慢性透析療法の現況 (1993年12月31日現在). 1994, 96-7.
 
23) 日本透析医学会. わが国の慢性透析療法の現況 (2007年12月31日現在). 2008, 表207.
 
24) Uldall, R. Slow nocturnal home hemodialysis at Wellesley hospital. Adv Ren Replace Ther. 3, 1996, 133-6.
PubMed
25) Lindsay, RM. The London, Ontario, daily/nocturnal hemodialysis study. Semin Dial. 17, 2004, 85-91.
PubMed
26) Pierratos, A. Daily (quotidian) nocturnal home hemodialysis : Nine years later. Hemodial Int. 8, 2004, 45-50.
PubMed
27) Rocco, MV. The effects of frequent nocturnal home hemodialysis : The Frequent Hemodialysis Network Nocturnal Trial. Kidney Int. 80, 2011, 1080-91.
PubMed
28) Pauly, RP. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant. 24, 2009, 2915-9.
PubMed
29) 金田浩. "長時間透析と限定自由食のすすめ". 続21世紀の慢性透析治療法と革命しよう : 長時間透析と限定自由食のすすめ. 三村信英監. 東京医学社, 2005, 15-45.
 
30) 日本透析医学会. 図説わが国の慢性透析療法の現況 (2011年12月31日現在). 2012, 21.
 
31) Schnediz, D. Compartment effects in hemodialysis. Semin Dial. 14, 2001, 271-7.
 
32) Goldfarb-Rumyantzev, AS. Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Am J Kidney Dis. 40, 2002, 1211-8.
PubMed
33) Clark, WR. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol. 10, 1999, 601-9.
PubMed
34) Leypoldt, JK. Kinetics of β2-microgrobulin and phosphate during hemodialysis : Effects of treatment frequency and duration. Semin Dial. 18, 2005, 401-8.
 
35) 金成泰. "透析時間". 血液浄化療法の指針 : 新しい方向性. 斎藤明ほか編. 日本メディカルセンター, 1997, 127-35.
 
36) Eloot, S. Impact of hemodialysis duration on the removal of uremic retension solutes. Kidney Int. 73, 2008, 765-70.
 
37) Basile, C. Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slowflow bicarbonate haemodialysis. Nephrol Dial Transplant. 26, 2011, 1296-303.
PubMed
38) Brunet, P. Treatment of haemodialysis : A randomized cross-over trial of 5-h versus 4-h treatment time. Nephrol Dial Transplant. 11 (suppl 8), 1996, 46-51.
 
39) Movilli, E. Association between high ultrafiltaration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant. 22, 2007, 3547-52.
PubMed
40) Flythe, JE. Rapid fluid removal during dialysis associated with cardiovascular morbidity and mortality. Kidney Int. 79, 2011, 250-7.
PubMed
41) Twardowski, ZJ. Short, thrice-weekly hemodialysis is inadequate regardless of small molecule clearance. Int J Artif Organs. 27, 2004, 452-66.
PubMed
42) Twardowski, ZJ. Treatment time and ultrafiltration rate are more important in dialysis prescription than small molecule clearance. Blood Purif. 25, 2007, 90-8.
PubMed
43) Charra, B. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol. 16, 1996, 35-44.
PubMed
44) Katzarski, KS. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant. 14, 1999, 369-75.
PubMed
45) Charra, B. Intensive dialysis and blood pressure control : A review. Hemodial Int. 8, 2004, 51-60.
PubMed
46) Chan, C. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heat failure. Nephrol Dial Transplant. 17, 2002, 1518-21.
 
47) Culleton, BF. Effects of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life. A randomized controlled trial. JAMA. 298, 2007, 1291-9.
PubMed
48) Kielstein, JT. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int. 59 (suppl 78), 2001, s9-s13.
 
49) Raj, DSC. Search of ideal hemodialysis : Is prolonged frequent dialysis the answer? Am J Kidney Dis. 34, 1999, 597-610.
 
50) Twardowski, ZJ. Effect of long-term increase in the frequency and/or prolongation of dialysis duration on certain clinical manifestations and results of laboratory investigations in patients with chronic renal failure. Hemodial Int. 8, 2004, 30-8.
PubMed
51) Curtis, J. Daily short and nightly nocturnal home hemodialysis : State of art. Dial Transplant. 33, 2004, 64-73.
 
52) Walsh, M. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int. 67, 2005, 1500-8.
 
53) 鈴木一之. 血液透析条件・透析量と生命予後-日本透析医学会の統計調査結果から-. 透析会誌. 43, 2010, 551-9.
 
54) Twardowski, ZJ. Fallacies of high-speed hemodialysis. Hemodial Int. 7, 2003, 10-117.
PubMed
55) Rainmann, J. Consequences of overhydration and the need for dry weight assessment. Contrib Nephrol. 161, 2008, 99-107.
 
56) Wystrychowski, G. Dry weight, sine qua non of adequate dialysis. Adv Chronic Kidney Dis. 14, 2007, e10-e16.
PubMed
57) Bleyer, A. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 55, 1999, 1533-9.
 
58) 原田欣子. 血液透析患者の透析曜日と入院リスクの関係. 腎と透析. 51 (suppl HDF療法 '01), 2001, 102-5.
 
59) Karnik, JA. Cardiac arrest and sudden death in dialysis units. Kidney Int. 60, 2001, 350-7.
PubMed
60) Bkeyer, AJ. Characteristics of sudden death in hemodialysis patients. Kidney Int. 69, 2006, 2268-73.
 
61) Genovesi, S. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol Dial Transplant. 24, 2009, 2529-36.
 
62) Foley, RN. Long interdialytic interval and mortality among patinets receiving hemodialysis. N Engl J Med. 365, 2011, 1099-107.
 
63) Zhang, H. Dialysis outcomes and analysis of practice patterns suggests the dialysis schedule affects day-ofweek mortality. Kidney Int. 81, 2012, 1108-15.
PubMed
64) DePalma, JR. A new automatic coil dialyzer system for 'daily' dialysis. Proc Eur Dial Transplant Assoc. 6, 1969, 26-34.
 
65) Kjellstrand, C. Daily hemodialysis : Dialysis for the next century. Adv Ren Replace Ther. 5, 1998, 267-74.
PubMed
66) Suri, RS. Daily hemodialysis : A sysytematic review. Clin J Am Soc Nephrol. 1, 2006, 33-42.
 
67) Punal, J. Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis : A systematic review. Nephrol Dial Transplant. 23, 2008, 2634-46.
PubMed
68) Kjellstrand, CM. Why daily hemodialysis is better : Decreased unphysiology. Semin Dial. 12, 1999, 472-7.
 
69) The FNH trial group. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 363, 2010, 2287-300.
 
70) Scribner, BH. Dialysis dose : Higher is better. J Am Soc Nephrol. 9, 1998, 899-900.
 
71) 日本透析医学会. わが国の慢性透析療法の現況 (2002年12月31日現在). 2003, 表124.
 
72) 日本透析医学会. わが国の慢性透析療法の現況 (2008年12月31日現在). 2009, 表1399.
 
73) 峰島三千男. "血液透析". 血液浄化療法ハンドブック. 改訂第3版. 透析療法合同専門委員会編. 協同医書出版社, 2004, 149-53.
 
74) 秋葉隆. 日本における国際血液透析患者調査DOPPSの成績. 透析会誌. 37, 2004, 1865-73.
 
75) Collins, AJ. "High-efficiency, high-flux therapies in clinical dialysis". Clinical dialysis. 3rd ed. Nissenson, AR. et al., eds. Appleton & Lange, 1995, 848-63.
 
76) 峰島三千男. "血液浄化効率に影響を与える因子 : 血液流量, 透析液流量 (基礎)". 血液浄化療法の指針 : 新しい方向性. 斎藤明ほか編. 日本メディカルセンター, 1997, 103-12.
 
77) 峰島三千男. クリアランスに及ぼす血流量, 透析液流量の影響. 臨牀透析. 14, 1998, 343-7.
 
78) Himmelfarb, J. "Hemodialysis". Brenner & Rector's the kidney. 8th ed. Brenner, BM., ed. W. B. Saunders, 2008, 1957-2006.
 
79) Sakiyama, R. Effect of bloof flow rate on internal filtration in a high-flux dialyzer with polysulfone membrane. J Artif Organs. 15, 2012, 266-71.
 
80) 日本透析医学会. わが国の慢性透析療法の現況 (2002年12月31日現在). 2003, 表125.
 
81) 日本透析医学会. わが国の慢性透析療法の現況 (2008年12月31日現在). 2009, 表1567.
 
82) Sigdell, JE. Clearance of a dialyzer under varying operating conditions. Artif Organs. 10, 1986, 219-25.
PubMed
83) 山下明泰. "逆濾過・逆拡散". 新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学社, 1998, 230-46.
 
84) 日本透析医学会. わが国の慢性透析療法の現況 (1999年12月31日現在). 2000, 976-9.
 
85) Leavey, SF. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis. 31, 1998, 997-1009.
PubMed
86) Lowrie, EG. Primary associates of mortality among dialysis patients : Trends and reassessment of Kt/V and urea reduction ratio as outcome-based measures of dialysis dose. Am J Kidney Dis. 32 (suppl 4), 1998, s16-s31.
 
87) Ronco, C. Technical and clinical evaluation of different short, highly efficient dialysis techniques. Contr Nephrol. 61, 1988, 46-68.
 
88) Ronco, C. Impact of high blood flows on vascular stability in haemodialysis. Nepnrol Dial Transplant. 5 (suppl 1), 1990, s109-s114.
 
89) Cheung, AK. Cardiac diseases in maintenance hemodialysis patients : Results of the HEMO study. Kidney Int. 65, 2004, 2380-9.
PubMed
90) Schmidt, DF. Inaccurate blood flow rate during rapid hemodialysis. Am J Kidney Dis. 17, 1991, 34-7.
PubMed
91) Rehman, SU. Intradialytic serial vascular access flow measurement. Am J Kidney Dis. 34, 1999, 471-7.
PubMed
92) Mehta, H. Correction of discrepancy between prescribed and actual blood flow rates in chronic hemodialysis patients with use of larger guage needles. Am J Kidney Dis. 39, 2002, 1231-5.
 
93) Sherman, RA. Rate-related recirculation : The effect of altering blood flow on dialyzer recirculation. Am J Kidney Dis. 17, 1991, 170-3.
PubMed
94) Hasbargen, JA. Variable blood pump flow rates and the effect on recirculation. Clin Nephrol. 42, 1994, 322-6.
PubMed
95) Twardowski, ZJ. Blood flow, negative pressure, and hemolysis during hemodialysis. Home Hemodial Int. 3, 1999, 45-50.
PubMed
96) 白石幸三. 長期透析患者における動静脈瘻の心機能への影響について. 透析会誌. 19, 1986, 673-8.
 
97) 多川斉. ブラッドアクセスと心機能. 臨牀透析. 12, 1996, 943-51.
 
98) Leypoldt, JK. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. Kideny Int. 51, 1997, 2013-7.
 
99) Leypoldt, JK. Increase in mass transfer-area coefficients and urea Kt/V with increasing dialysate flow rate are greater for high-flux dialyzers. Am J Kidney Dis. 38, 2001, 575-9.
 
100) Mandolfo, S. Impact on blood and dialysate flow and surface on performance of new polysulfone hemodialysis dialyzers. Int J Artif Organs. 26, 2003, 115-20.
 
101) 峰島三千男. 総括物質移動係数とダイアライザの性能評価式. 臨牀透析. 14, 1998, 469-73.
 
102) 峰島三千男. ダイアライザ性能評価式の利用法. 臨牀透析. 14, 1998, 873-8.
 
103) 山下明泰. ダイアライザの効果的な使い方. 臨牀透析. 15, 1988, 1157-61.
 
104) Laville, M. Nutritional aspects in hemodialysis. Kidney Int. 58 (suppl 76), 2000, s133-s139.
 
105) Pupim, LB. Nutrition and metabolism in kidney disease. Semin Nephrol. 26, 2006, 134-57.
PubMed
106) Garibotto, G. Amino acid loss with polyethersulfone. Contirb Nephrol. 138, 2003, 59-67.
PubMed
107) 椿原美治. 慢性血液透析患者における蛋白・アミノ酸代謝異常と必須アミノ酸療法の検討. 日腎会誌. 24, 1982, 1127-36.
 
108) Pupim, LB. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest. 110, 2002, 483-92.
PubMed
109) Fouque, D. EBPG Guideline on nutrition. Nephrol Dial Transplant. 22 (suppl 2), 2007, ii45-ii87.
 
110) 金田浩. 透析施設における長時間透析の現状と問題点 : 「長時間透析+限定自由食」の取組み. 臨牀透析. 26, 2010, 161-8.
 
111) Babb, AL. The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Intern Organs. 17, 1971, 81-91.
PubMed
112) Henderson, LW. Clinical response to maintenance hemodiafiltration. Kidney Int. 7 (Suppl), 1975, 58-65.
 
113) Quellhorst, E. Treatment of chronic uremia by an ultrafiltration kidney-First clinical experience. Proc Eur Dial Transplant Assoc. 13, 1976, 314-8.
 
114) 佐藤威. 各種の血液浄化法の機能と適応 : 血液浄化器の性能評価法と機能分類. 透析会誌. 29, 1996, 1231-45.
 
115) 斎藤明. Protein losing hemofilterの臨床と濾過液の中・高分子量物質の分析. 人工臓器. 10, 1981, 907-10.
 
116) 斎藤明. Protein-permeable hemofiltersの除去性能 : 糸球体濾過への接近. 人工臓器. 13, 1984, 1303-13.
 
117) Gejyo, F. A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun. 129, 1985, 701-6.
 
118) 峰島三千男. ふるい係数の定義. 臨牀透析. 14, 1998, 1499-503.
 
119) 峰島三千男. ふるい係数に及ぼす血流量, ろ液流量の影響. 臨牀透析. 14, 1998, 1611-4.
 
120) 峰島三千男. 真のふるい係数と反射係数. 臨牀透析. 14, 1998, 1725-9.
 
121) 飯田喜俊. "透析療法の実際". 新標準透析療法. 飯田喜俊ほか編. 中外医学社, 2001, 91-110.
 
122) 川西秀樹. 新たな透析液水質基準と血液浄化器の機能分類. 透析会誌. 38, 2005, 149-54.
 
123) Koda, Y. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int. 52, 1997, 1096-101.
PubMed
124) 甲田豊. "臨床症状の改善効果". 新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学社, 1998, 158-70.
 
125) van Ypersele, C. Amyloidosis and its relationship to different dialyzers. Nephrol Dial Transplant. 9 (suppl 2), 1994, 156-61.
 
126) 日本透析医学会. わが国の慢性透析療法の現況 (1998年12月31日現在). 1999, 表243, 表251.
 
127) 日本透析医学会. わが国の慢性透析療法の現況 (2002年12月31日現在). 2003, 表66, 表67.
 
128) 日本透析医学会. わが国の慢性透析療法の現況 (2008年12月31日現在). 2009, 表1843, 表1999.
 
129) 川西秀樹. 血液浄化器 (中空糸型) の機能分類2013. 透析会誌. 46, 2013, 501-6.
 
130) 石崎允. 高性能膜素材の体内溶質移動に及ぼす影響 : 2プールモデルによる解析. 腎と透析. 36 (suppl ハイパフォーマンスメンブレン '94), 1994, 225-8.
 
131) 及川一彦. EVAL膜 (KF-C) の溶質および体液の細胞内外移動に対する影響. 腎と透析. 43 (suppl ハイパフォーマンスメンブレン '97), 1997, 83-5.
 
132) 佐藤元美. 血液透析患者における微小循環に対する透析膜の影響. 腎と透析. 53 (suppl ハイパフォーマンスメンブレン '02), 2002, 122-4.
 
133) 牟田俊幸. 膜素材による透析中のアミノ酸漏出の差は単にダイアライザーの除去性能によるものだろうか. 腎と透析. 63 (suppl ハイパフォーマンスメンブレン '07), 2007, 290-3.
 
134) 及川一彦. 同一膜素材の継続使用におけるβ-2MG, MG産生能およびKt/Vの変動. 腎と透析. 32 (suppl ハイパフォーマンスメンブレン '92), 1992, 133-61.
 
135) 川西秀樹. "血液浄化療法の実際 : 血液濾過療法". 血液浄化療法ハンドブック. 改訂第3版. 透析療法合同専門委員会編. 協同医書出版社, 2004, 153-61.
 
136) 水口潤. 低分子量蛋白領域の尿毒症物質除去とアルブミン損失. 腎と透析. 65 (別冊ハイパフォーマンスメンブレン '08), 2008, 18-22.
 
137) 衣笠えり子. "HPM-HD, HF, HDFの臨床". HDF療法ハンドブック. 日本HDF研究会編. 南江堂, 2000, 110-6.
 
138) 金成泰. "大量液置換血液浄化法". 血液浄化療法の指針 : 新しい方向性. 斎藤明ほか編. 日本メディカルセンター, 1997, 55-76.
 
139) 斎藤明. アルブミンはどれだけ除去すればよいのか. 腎と透析. 65 (suppl ハイパフォーマンスメンブレン '08), 2008, 8-12.
 
140) 金成泰. "ハイパフォーマンスダイアライザーでは改善されない症状". 新しいハイパフォーマンスダイアライザー. 竹沢真吾編. 東京医学社, 1998, 171-82.
 
141) 金成泰. "大量液置換HDF : とくにon-line HDFの臨床効果". HDF療法ハンドブック. 日本HDF研究会編. 南江堂, 2000, 134-40.
 
142) 金成泰. オンラインHDFが目指すもの. 腎と透析. 38 (suppl ハイパフォーマンスメンブレン '95), 1995, 47-53.
 
143) 金成泰編. "HDFの臨床". 実践的アプローチ透析液水質管理＆オンラインHDF. メディカルレビュー社, 1996, 205-40.
 
144) Canaud, B. On-line haemodiafiltration. Safety and efficacy in long-term clinical practice. Nephrol Dial Transplant. 15 (suppl 1), 2000, 60-7.
 
145) van Laecke, S. Online hemodiafiltration. Artif Organs. 30, 2006, 579-85.
PubMed
146) Canaud, B. Overview of clinical studies in hemodiafiltration : What do we need now? Hemodial Int. 10 (suppl 1), 2006, s5-s12.
 
147) Ronco, C. Hemodiafiltration history, technology, and clinical results. Adv Chronic Kidney Dis. 14, 2007, 231-43.
PubMed
148) van der Weerd, NC. Haemodiafiltration, promise for the future? Nephrol Dial Transplant. 23, 2008, 438-43.
PubMed
149) Bammens, B. Improving removal of protein-bound retention solute. Contrib Nephrol. 149, 2005, 175-84.
PubMed
150) Lornoy, W. Impact of convective flow on phosphorus removal in maintenance hemodialysis patients. J Ren Nutr. 16, 2006, 47-53.
PubMed
151) Lindsay, RM. The London daily/nocturnal hemodialysis study-study design, morbidity, and mortality results. Am J Kidney Dis. 42 (suppl 1), 2003, s5-s12.
 
152) Canaud, B. Mortality risk for patients receiving hemodiafiltration versus hemodialysis : European results from the DOPPS. Kidney Int. 69, 2006, 2087-93.
PubMed
153) Vilar, E. Long-term outcomes in online hemodiafiltration and high-flux hemodialysis : a comparative analysis. Clin J Am Soc Nephrol. 4, 2009, 1944-53.
PubMed
154) Grooteman, MP. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol. 23, 2012, 1087-96.
PubMed
155) Ok, E. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis : results from the Turkish OL-HDF study. Nephrol Dial Transplant. 28, 2013, 192-202.
PubMed
156) Maduell, F. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 24, 2013, 487-97.
PubMed
157) 桜林耐. "尿素窒素". 透析患者の検査値の読み方. 第2版. 深川雅史ほか編. 日本メディカルセンター, 2007, 51-3.
 
158) 木村玄次郎. "透析療法への定量的アプローチ". 腎不全. 阿部正和ほか編. 金原出版, 1986, 254-68.
 
159) 木村玄次郎. Urea kineticsとKt/V. 臨床医. 21, 1995, 222-6.
 
160) Lowrie, EG. Clinical example of pharmacokinetic and metabolic modeling : quantitative and individualized prescription of dialysis therapy. Kidney Int. 10 (Suppl), 1980, S11-6.
PubMed
161) Gotch, FA. "Kinetic modeling in hemodialysis". Clinical dialysis. 3rd ed. Nissenson, AR. et al., eds. Appleton & Lange, 1995, 156-88.
 
162) Daugirdas, JT. "Physiologic principles and urea kinetic modeling". Handbook of dialysis. 3rd ed. Daugirdas, JT. et al., eds. Lippincott Williams & Wilkins, 2001, 15-45.
 
163) Daugirdas, JT. Second generation logarithmic estimates of single-pool variable volume Kt/V : an analysis of error. J Am Soc Nephrol. 4, 1993, 1205-13.
 
164) Shinzato, T. Determination of Kt/V and protein catabolic rate using pre-and postdialysis blood urea nitrogen concentrations. Nephron. 67, 1994, 280-90.
 
165) Daugirdas, JT. "Urea kinetic modeling : Table and Figures". Handbook of dialysis. 3rd ed. Daugirdas, JT. et al., eds. Lippincott Williams & Wilkins, 2001, 667-76.
 
166) 峰島三千男. 血液浄化効率表現の比較検討. Clinical Engineering. 10, 1999, 369-73.
 
167) National Kidney Foundation. "Blood urea nitrogen (BUN) sampling". Clinical practice guidelines. NKFDOQI, 1997, 51-61.
 
168) Kong, CH. The effect of exercise during haemodialysis on solute removal. Nephrol Dial Transplant. 14, 1999, 2927-31.
PubMed
169) Collins, AJ. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis. 23, 1994, 272-82.
PubMed
170) Hakim, RM. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis. 23, 1994, 661-9.
PubMed
171) Owen, WF. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Eng J Med. 329, 1993, 1001-6.
 
172) Parker, TF. Survival of hemodialysis patients in the United States is improved with greater quantity of dialysis. Am J Kidney Dis. 23, 1994, 670-80.
PubMed
173) Held, PJ. The dose of hemodialysis and patient mortality. Kidney Int. 50, 1996, 550-6.
PubMed
174) Bloembergen, WE. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int. 50, 1996, 557-65.
PubMed
175) National Kidney Foundation. K/DOQI Clinical practice guidelines for hemodialysis adequacy, 2000. Am J Kidney Dis. 37 (suppl 1), 2001, s7-64.
 
176) Eknoyan, G. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 347, 2002, 2010-9.
PubMed
177) National Kidney Foundation. Clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis. 48 (Suppl 1), 2006, s12-s47.
 
178) 日本透析医学会. わが国の慢性透析療法の現況 (2001年12月31日現在). 2002, 559.
 
179) Himmerfarb, J. Success and challenge in dialysis therapy. N Eng J Med. 347, 2002, 2068-70.
 
180) Depner, TA. How will the results of the HEMO study impact dialysis practice? Semin Dial. 16, 2003, 8-11.
PubMed
181) Lindsay, RM. How will the results of the HEMO study impact dialysis practice? Semin Dial. 16, 2003, 16-9.
PubMed
182) Locatelli, F. Dose of dialysis, convection and haemodialysis patients outcome? what HEMO study doesn't tell us : European viewpoint. Nephrol Dial Transplant. 18, 2003, 1061-5.
PubMed
183) 秋葉隆. "The hemodialysis studyの意味するもの". Annual review 2003. 中外医学社, 2003, 156-9.
 
184) Greene, T. What did we learn from the HEMO study? Implications of secondary analyses. Contrib Nephrol. 149, 2005, 69-82.
PubMed
185) Lowrie, EG. Primary associations of mortality among dialysis patients : Trends and reassessment of Kt/V and urea reduction ratio as outcome-based measures of dialysis dose. Am J Kidney Dis. 32 (suppl 6), 1998, s16-s31.
 
186) Chertow, GM. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int. 56, 1999, 1872-8.
 
187) Salahudeen, AK. Risk factors for higher mortality at the highest levels of spKt/V in haemodialysis patients. Nephrol Dial Transplant. 18, 2003, 1339-44.
 
188) Lowrie, EG. The urea {clearance x dialysis time} product (Kt) as an outcome-based measure of hemodialysis dose. Kidney Int. 56, 1999, 729-37.
PubMed
189) Li, Z. Comparing the urea reduction ratio and the urea product as outcome-based measures of hemodialysis dose. Am J Kidney Dis. 35, 2000, 598-605.
 
190) Lowrie, EG. The normalized treatment ratio (Kt/V) is not the best dialysis parameter. Blood Purif. 18, 2000, 286-94.
 
191) Port, FK. High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis. 43, 2004, 1014-23.
PubMed
192) Depner, T. Dialysis dose and the effect of gender and body size on outcome in the HEMO study. Kidney Int. 65, 2004, 1386-94.
PubMed
193) Wolfe RA. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis. 35, 2000, 80-8.
PubMed
194) Leavey, SF. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients : results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 16, 2001, 2386-94.
PubMed
195) Port, FK. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol. 13, 2002, 1061-6.
PubMed
196) Sarkar, SR. Metabolic consequences of body size and body composition in hemodialysis patients. Kidney Int. 70, 2006, 1832-9.
PubMed
197) Kotanko, P. The impact of visceral mass on survival in chronic hemodialysis patients. Int J Artif Organs. 30, 2007, 993-9.
PubMed
198) Spalding, EM. Kt/V underestimates the hemodialysis dose in women and small man. Kidney Int. 74, 2008, 348-55.
 
199) Singer, MA. Mouse to elephant : biological scaling and Kt/V. Am J Kidney Dis. 35, 2000, 306-9.
 
200) Ross Morton, A. The problem with Kt/V : Dialysis dose should be normalized to metabolic rate not volume. Semin Dial. 20, 2007, 12-5.
 
201) Daugirdas, JT. Comparison of proposed alternative methods for rescaling dialysis dose : Resting energy expenditure, high metabolic rate organ mass, liver size, and body surface area. Semin Dial. 21, 2008, 377-84.
PubMed
202) Daugirdas, JT. Surface-area-normalized Kt/V : A method of rescaling dialysis dose to body surface area? Implications for different-size patients by gender. Semin Dial. 21, 2008, 415-21.
 
203) 石崎允. HPM透析におけるKt/Vの信頼性. 腎と透析. 40 (suppl ハイパフォーマンスメンブレン '96), 1996, 172-5.
 
204) Vanholder, R. Review on uremic toxins : Classification, concentration, and interindividual variability. Kidney Int. 63, 2003, 1934-43.
PubMed
205) Vanholder, R. Adequacy of dialysis : A critical analysis. Kidney Int. 42, 1992, 540-8.
PubMed
206) Eloot, S. Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds : a kinetic analysis. Nephrol Dial Transplant. 34, 2009, 2225-32.
 
207) 伊藤喜久. β2-マイクログロブリン. 日本臨牀. 62 (suppl 11), 2004, 255-7.
 
208) 日本透析医学会. わが国の慢性透析療法の現況 (2000年12月31日現在). 2001, 510-1.
 
209) Cheung, AK. Serum beta-2 microglobulin levels predict mortality in dialysis patients : Results of the HEMO study. J Am Soc Nephrol. 17, 2006, 546-55.
PubMed
210) Okuno, S. Serum beta 2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant. 24, 2009, 571-7.
PubMed
211) 日本透析医学会. 図説わが国の慢性透析療法の現況 (2008年12月31日現在). 2009, 83.
 
212) Goldfarb-Rumyantzev, AS. Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Am J Kidney Dis. 40, 2002, 1211-8.
PubMed
213) Depner, TA. Uremic toxicity : Urea and beyond. Semin Dial. 14, 2001, 246-51.
PubMed
214) Charra, B. Dialysis overdose : Fact or reality? Hemodial Int. 8, 2004, 316-9.
PubMed

4章 水分と塩分のコントロール

P.123 掲載の参考文献
1) Rainmann, J. Consequences of overhydration and the need for dry weight assessment. Contrib Nephrol. 161, 2008, 99-107.
 
2) Rainmann, J. A fresh look at dry weight. Hemodial Int. 12, 2008, 395-405.
 
3) Wystrychowski, G. Dry weight : Sine qua non of adequate dialysis. Adv Chronic Kidney Dis. 14, 2007, e10-e16.
PubMed
4) 日本透析医学会. わが国の慢性透析療法の現況 (2011年12月31日現在). 2012, 表229.
 
5) Thomson, GE. Hemodialysis for chronic renal failure. Arch Intern Med. 120, 1967, 153-67.
PubMed
6) Henderson, LW. Symptomatic hypotension during hemodialysis. Kidney Int. 17, 1980, 571-6.
PubMed
7) Charra, B. Clinical assessment of dry weight. Nephrol Dial Transplant. 11 (suppl 2), 1996, s16-s19.
 
8) Daugirdas, JT. "Chronic hemodialysis prescription : A urea kinetic approach". Handbook of dialysis. 3rd ed. Daugirdas, JT. et al., eds. Lippincott Williams & Wilkins, 2001, 121-47.
 
9) 日本透析医学会. 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌. 44, 2011, 337-425.
 
10) Charra, B. Blood pressure control in dialysis patiets : Importance of the lag phenomenon. Am J Kidney Dis. 32, 1998, 720-4.
 
11) Perazella, MA. Approach to patients with intradialytic hypotension : A focus on therapeuitic options. Semin Dial. 12, 1999, 175-81.
 
12) Daugirdas, JT. Pathophysiology of dialysis hypotension : An update. Am J Kidney Dis. 38 (suppl 4), 2001, s11-s17.
 
13) Sherman, RA. Intradialytic hypotension : An overview of recent, unsolved and overlooked issues. Semin Dial. 15, 2002, 141-3.
 
14) Shoji, T. Definition of intradialytic hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 66, 2004, 1212-20.
 
15) Mizumasa, T. Dialysis-related hypotension as a cause of progressive frontal lobe atrophy in chronic hemodialysis patients : A 3-year prospective study. Nephron Clin Pract. 97, 2004, c23-c30.
PubMed
16) Charra, B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int. 11, 2007, 21-31.
PubMed
17) De Vries, JPM. Non-invasive monitoring of blood volume during hemodialysis : Its relation with post-dialytic dry weight. Kidney Int. 44, 1993, 851-4.
 
18) Poggi, A. Cardiothoracic ratio as a guide to ultrafiltration therapy in dialyzed patients. Int J Artif Organs. 3, 1980, 332-7.
PubMed
19) Don, C. Body fluid volume status in hemodialysis patients : The value of the chest radiograph. J Can Assoc Radiol. 41, 1990, 123-6.
 
20) 原沢博文. 長期透析患者の溢水の指標としての心胸比および心横径の有用性. 日医放線会誌. 49, 1989, 191-8.
 
21) 安藤康宏. 超音波断層法による血液透析中の下大静脈内径変化の検討. 透析会誌. 18, 1985, 173-9.
 
22) Ando, Y. The inferior vena cava diameter as a marker of dry weight in chronic hemodialyzed patients. Artif Organs. 19, 1995, 1237-42.
 
23) 草野英二. 画像診断によるdry weightの設定. Clinical Engineering. 11, 2000, 304-8.
 
24) Wilkins, MR. Changes in plasma immunoreactive atrial natoriuretic peptide during sequential ultrafiltration and haemodialysis. Clin Sci. 71, 1986, 157-60.
 
25) Joffy, S. Natriuretic peptides in ESRD. Am J Kidney Dis. 46, 2005, 1-10.
PubMed
26) 海津嘉蔵. ナトリウム利尿ペプチドを水分管理指標とする意味. Clinical Engineering. 11, 2000, 309-15.
 
27) 石井恵理子. 血液透析 (HD) 患者の血中心房性ナトリウム利尿ペプチド (ANP) 値によるドライウェイト (DW) の判断基準に関する検討. 透析会誌. 37, 2004, 1417-22.
 
28) Suresh, M. Natriuretic peptides and the dialysis patient. Semin Dial. 18, 2005, 409-19.
PubMed
29) Wang, AY. Clinical utility of natriuretic peptides in dialysis patients. Semin Dial. 25, 2012, 326-33.
PubMed
30) Bwdogni, G. Accuracy of an eight-point tactile-electrode impedance method in the assessment of total body water. Eur J Cin Nutr. 56, 2002, 1143-8.
 
31) Wang, Z. The five-level model : a new approach to organizing body-composition research. Am J Clin Nutr. 56, 1992, 19-28.
 
32) Papakrivopoulou, E. Comparison of volume status in asymptomatic haemodialysis and peritoneal dialysis outpatients. Nephron Extra. 2, 2012, 48-54.
PubMed
33) 佐々木信博. 高精度体成分分析 (InBody S20) を用いた血液透析患者の体液量評価 : 生体電気インピーダンス (BIA) はDWの指標になり得るか? 透析会誌. 40, 2007, 581-8.
 
34) 佐々木信博. 生体電気インピーダンス (BIA) 法によるDW設定基準 : 高精度体成分分析装置 (InBody S20) による浮腫値 (ECF/TBW) での検討. 透析会誌. 41, 2008, 723-30.
 
35) Hara, N. Value of the extracellular water ratio for assessment of cirrhotic patients with and without ascites. Hepatol Res. 39, 2009, 1072-9.
PubMed
36) Steuer, RR. A new optical technique for monitoring hematocrit and circulating blood volume : Its application in renal dialysis. 22, 1993, 260-5.
 
37) 川西秀樹. 血液透析中の循環血液量測定 : 非観血式連続的Hematovrit測定装置 CRIT-LINETMの有用性. 人工臓器. 24, 1995, 732-5.
 
38) 田部井薫. 除水による蛋白濃縮度の意義の検討. 透析会誌. 32, 1999, 1071-7.
 
39) 田部井薫. "透析低血圧におけるショック時の対応". 透析Strategy 3 : 透析療法に伴う心血管系合併症とその阻止対策. 中外製薬, 2001, 31-9.
 
40) Kooman, JP. Wet or dry in dialysis? Can new technologies help? Semin Dial. 22, 2009, 9-12.
PubMed
41) 日本透析医学会. 維持血液透析ガイドライン : 血液透析処方. 透析会誌. 46, 2013, 587-632.
 
42) 日本腎臓学会編. "食事療法". 腎疾患の生活指導・食事療法ガイドライン. 東京医学社, 1998, 71-93.
 
43) 日本透析医学会. わが国の慢性透析療法の現況 (1999年12月31日現在). 2000, 983.
 
44) Saran, R. Nonadherence in hemodialysis : Association with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int. 64, 2003, 254-62.
PubMed
45) Rahman, M. Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. Am J Kidney Dis. 35, 2000, 257-65.
PubMed
46) Kalantar-Zadeh, K. Fluid retension is associated with cardiovasucular mortality in patients undergoing longterm hemodialysis. Circulation. 119, 2009, 671-9.
 
47) Foley, RN. Blood pressure and long-term mortality in United States hemodialysis patients ; USRDS wave 3 and 4 study. Kidney Int. 62, 2002, 1784-90.
 
48) Lopez-Gomez, JM. Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. Kidney Int. 67 (suppl 93), 2005, s63-s68.
 
49) Testa, A. The other side of coin : Interdialytic weight gain as an index of good nutrition. Am J Kidney Dis. 31, 1998, 830-4.
PubMed
50) Ronco, C. Impact of high blood flows on vascular stability in haemodialysis. Nephrol Dial Transplant. 5 (suppl 1), 1990, s109-s114.
 
51) Saran, R. Longer treatment time and slower ultrafiltration in hemodialysis : Associations with reduced mortality in the DOPPS. Kidney Int. 69, 2006, 1222-8.
PubMed
52) Movilli, E. Association between high ultrafiltration rates and mortality in ureamic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant. 22, 2007, 3547-52.
 
53) Flythe, JE. Rapid fluid removal during dialysis associated with cardiovascular morbidity and mortality. Kidney Int. 79, 2011, 250-7.
PubMed
54) 河原克雅. "体液の調節". 標準生理学. 第6版. 本郷利憲ほか編. 医学書院, 2005, 760-64.
 
55) Fouque, D. EBPG guideline on nutrition. Nephrol Dial Transplant. 22 (suppl 2), 2007, ii45-ii87.
 
56) 木村玄次郎. 透析患者における食事摂取量の定量的算出. 腎と透析. 19, 1985, 605-10.
 
57) Locatelli, F. Dry weight and sodium balance. Semin Nephrol. 21, 2001, 291-7.
PubMed
58) Keen, ML. The association of the sodium "setpoint" to interdialytic weight gain and blood pressure in hemodialysis patients. Int J Artif Organs. 30, 2007, 971-9.
PubMed
59) Flanigan, MJ. Role of sodium in hemodialysis. Kidney Int. 58 (suppl 76), 2000, s72-s78.
 
60) Ozkahya, M. Long-term survival rates in haemodialysis patients treated with strict volume control. Nephrol Dial Trasplant. 21, 2006, 3506-13.
 
61) 政金生人. 超低塩レシピ. 腎不全を生きる. 31, 2005, 49-55.
 
62) 大橋俊夫. "血液循環". 標準生理学. 第6版. 本郷利憲ほか編. 医学書院, 2005, 561-95.
 
63) Tabei, K. An index of plasma refilling in hemodialysis patients. Nephron. 74, 1996, 266-74.
PubMed
64) De Vries, PM. Plasma volume changes during hemodialysis. Semin Dial. 5, 1992, 42-7.
 
65) Leypoldt, JK. Hemodynamic monitoring during hemodialysis. Adv Renal Replace Ther. 6, 1999, 233-42.
PubMed
66) Rothe, CF. Reflux control of vein and vascular capacitance. Physiol Rev. 63, 1983, 1281-342.
 
67) Shibagaki, Y. Significant reduction of the large-vessel blood volume by food intake during hemodialysis. Clin Nephrol. 49, 1996, 49-54.
 
68) 鈴木昌幸. 維持透析患者の循環血液量に及ぼす体位変換の影響. 透析会誌. 33, 2000, 1325-7.
 
69) Barakat, MM. Hemodynamic effects of intradialytic food ingestion and the effect of caffeine. J Am Soc Nephrol. 3, 1993, 1813-8.
PubMed
70) Daugirdas, JT. Dialysis hypotension : A hemodynamic analysis. Kidney Int. 39, 1991, 233-46.
PubMed
71) Leunissen, KML. Dialysis hypotension. Int J Artif Organs. 21, 1998, 771-3.
 
72) 荻本剛一. 透析低血圧の病態生理. 臨牀透析. 19, 2003, 171-7.
 
73) Sherman, R. Modifying the dialysis prescription to reduce intradialytic hypotension. Am J Kidney Dis. 38 (suppl 4), 2001, s18-s25.
 
74) Palmer, BF. Recent advances in the prevention and management of intradialytic hypotension. J Am Soc Nephrol. 19, 2008, 8-11.
 
75) Kooman, J. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant. 22 (suppl 2), 2007, ii22-ii44.
 
76) Donauer, J. Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects. Am J Kidney Dis. 36, 2000, 115-23.
PubMed
77) 木村玄次郎. "透析療法への定量的アプローチ". 腎不全. 阿部正和ほか編. 金原出版, 1986, 254-68.
 
78) Stiller, S. A critical review of sodium profiling for hemodialysis. Semin Dial. 14, 2001, 337-47.
PubMed
79) Maggiore, Q. Vascular stability and heat in dialysis patients. Contrib Nephrol. 41, 1984, 398-402.
PubMed
80) Maggiore, Q. Thermal balance and dialysis hypotension. Int J Artif Organ. 9, 1995, 518-25.
 
81) Kong, CH. The effect of exercise during haemodialysis on solute removal. Nephrol Dial Transplant. 14, 1999, 2927-31.
PubMed
82) Patient registration committee, Japanese society for dialysis therapy. An overview of regular dialysis treatment in Japan as of 31 December, 2003. Ther Apher Dial. 9, 2005, 431-58.
PubMed
83) Chazot, C. Intradialytic hypertension : It is time to act. Nephron Clin Pract. 115, 2010, c182-8.
PubMed
84) Inrig, JK. Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients. Kidney Int. 71, 2007, 454-61.
PubMed
85) 日本透析医学会. わが国の慢性透析療法の現況 (2001年12月31日現在). 2002, 1-27.
 
86) Agarwal, R. Intradialytic hypertension is a marker of volume excess. Nephrol Dial Transplant. 25, 2010, 3355-61.
PubMed
87) Locatelli, F. The growing problem of intradialytic hypertension. Nat Rev Nephrol. 6, 2010, 41-8.
PubMed

5章 しっかり食べて、しっかり透析する

P.175 掲載の参考文献
1) 香川靖雄ほか. "代謝". ナースのための生化学・栄養学. 改訂第4版. 南山堂, 2006, 53-118.
 
2) 武田英二. "蛋白質". 医師, 管理栄養士のための栄養代謝テキスト. 文光堂, 1997, 37-48.
 
3) Bergstrom, J. Nutrition and morality in hemodialysis. J Am Soc Nephrol. 6, 1995, 1329-41.
 
4) Mitch, WE. Factors causing malnutrition in patients with chronic uremia. Am J Kidney Dis. 33, 1999, 176-9.
PubMed
5) Laville, M. Nutritional aspects in hemodialysis. Kidney Int. 58 (suppl 76), 2000, s133-s139.
 
6) Pupim, LB. Nutrition and metabolism in kidney disease. Semin Nephrol. 26, 2006, 134-57.
PubMed
7) Neyra, R. Increased resting energy expenditure in patients with end-stage renal disease. J Parent Ent Nutr. 27, 2003, 36-42.
 
8) Kopple, JD. The free and bound amino acids removed by hemodialysis. Trans Am Soc Artif Intern Organs. 19, 1973, 309-13.
 
9) Wolfson, M. Amino acid losses during hemodialysis with infusion of amino acid and glucose. Kidney Int. 21, 1982, 500-6.
PubMed
10) Ikizler, T. Amino acid and albumin losses during hemodialysis. Kidney Int. 46, 1994, 830-7.
PubMed
11) Navarro, JF. Effect of different membranes on amino-acid losses during haemodialysis. Nephrol Dial Transplant. 13, 1998, 113-7.
PubMed
12) Ikizler, TA. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physol Endocrinol Metab. 282, 2002, e107-e116.
 
13) Veeneman, JM. Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. Am J Physiol Endocrinol Metab. 284, 2003, e954-e965.
PubMed
14) Ikizler, TA. Increased energy expenditure in hemodialysis patients. J Am Soc Nephrol. 7, 1996, 2646-53.
PubMed
15) Kopple, JD. Protein-energy malnutrition in maintenance dialysis patients. Am J Clin Nutr. 65, 1997, 1544-57.
PubMed
16) 伊藤美紀子. "栄養不良の定義". 腎不全医療における栄養管理の基礎知識. 加藤明彦ほか編. 日本メディカルセンター, 2011, 71-81.
 
17) Fouque, D. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 73, 2008, 391-8.
PubMed
18) Carrero, JJ. Etiology of the protein-energy wasting syndrome in chronic kidney disease : A consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr. 23, 2013, 77-90.
PubMed
19) Man, NK. "Adequacy of hemodialysis, nutrition, and dialysis prescription". Long-term hemodialysis. Kluwer Academic Publishers, 1995, 49-60.
 
20) Stenvinkel, P. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int. 55, 1999, 1899-911.
PubMed
21) Stenvinkel, P. Are there two types of malnutrition in chronic renal failure? Evidence for relationship between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 15, 2000, 953-60.
PubMed
22) Pollock, CA. Nutritional markers and survival in maintenance dialysis patients. Nephron. 74, 1996, 625-41.
PubMed
23) Kalantar-Zadeh, K. Recent advances in understanding the malnutrition - inflammation - cachexia syndrome in chronic kidney disease patients : What is next. Semin Dial. 18, 2005, 365-9.
PubMed
24) Azar, AT. Association between dialysis dose improvement and nutritional status among hemodialysis patients. Am J Nephrol. 27, 2007, 113-9.
PubMed
25) Kalantar-Zadeh, K. Malnutrition-inflammation complex syndrome in dialysis patients : Causes and consequences. Am J Kidney Dis. 42, 2003, 864-81.
PubMed
26) Carrero, JJ. Inflammation in end-stage renal disease--What have we learned in 10 years? Semin Dial. 23, 2010, 498-509.
PubMed
27) 佐中孜. "透析患者". 腎疾患患者の食事療法の手引き. 日本腎臓学会編. 東京医学社, 1999, 79-82.
 
28) 臼井昭子. "透析食とその考え方". 透析食ガイドブック. 改訂3版. 日本メディカルセンター, 2006, 15-46.
 
29) K/DOQI National Kidney Foundation. Clinical practice guidelines for nutrition of chronic renal failure. Am J Kidney Dis. 35 (suppl 2), 2000, s1-s140.
 
30) Fouque, D. EBPG guideline on nutrition. Nephrol Dial Transplant. 22 (suppl 2), 2007, ii45-ii87.
 
31) Burrows, JD. Effects of dietary intake, appetite, and eating habits on dialysis and non-dialysis treatment days in hemodialysis patients : Cross-sectional results from the HEMO study. J Ren Nutr. 13, 2003, 191-8.
 
32) Qunibi, WY. Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int. 66 (Suppl 90), 2004, s8-s12.
 
33) Gonzalez-Parra, E. Phosphorus and nutrition in chronic kidney disease. Int J Nephrol. 2012, 597605. EPub2012 May30.
 
34) 藤井正満. "Ca, Pの摂取". EBM血液浄化療法. 飯田喜俊ほか編. 金芳堂, 2000, 415-22.
 
35) Uribarri, J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial. 20, 2007, 295-301.
PubMed
36) Sherman, RA. Dietary phosphate restriction and protein intake in dialysis patients : A misdirected focus. Semin Dial. 20, 2007, 16-9.
PubMed
37) 山中慎太郎. "透析条件変更による高P血症対策".ガイドラインサポートハンドブック : 慢性腎臓病に伴う骨・ミネラル代謝異常 (CKD-MBD). 改訂版. 横山啓太郎編. 医薬ジャーナル社, 2013, 222-30.
 
38) Kalantar-Zadeh, K. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 5, 2010, 519-30.
PubMed
39) Cupisti, A. Management of natural and added dietary phosphorus burden in kidney disease. Semin Nephrol. 33, 2013, 180-90.
PubMed
40) Lee, RD., Nieman, DC. "Clinical assessment of nutritional status". Nutritional assessment. 3rd ed. McGraw-Hill, 2003, 338-55.
 
41) 兵藤透. Subjective global assessmentによる透析患者の栄養評価. 臨牀透析. 20, 2004, 1521-6.
 
42) Kalanter-Zadeh, K. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 38, 2001, 1251-63.
 
43) Rambod, M. Association of malnutrition- inflammation score with quality of life and mortality in hemodialysis patients : A 5-year prospective cohort study. Am J Kidney Dis. 53, 2009, 298-309.
PubMed
44) Bouillanne, O. Geriatric nutritional risk index : a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 82, 2005, 777-83.
PubMed
45) Yamada, K. Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr. 87, 2008, 106-13.
PubMed
46) 上西一弘. "身体計測". 臨床栄養管理. 中村丁次ほか編. 第一出版, 1997, 93-102.
 
47) 小沢尚. 身体計測法による透析患者の栄養評価. 臨牀透析. 20, 2004, 1507-12.
 
48) 日本人の新身体計測基準値JARD. 栄養評価と治療. 19 (suppl), 2001, s45-s81.
 
49) 藤野陽子. DEXAによる透析患者の栄養評価. 臨牀透析. 20, 2004, 1513-9.
 
50) 松永智仁. 栄養アセスメントの方法 (1) 身体計測. 臨牀透析. 19, 2003, 1671-6.
 
51) 中尾俊之. Bioelectrical impedance analysis (BIA) による透析患者の栄養評価. 臨牀透析. 20, 2004, 1521-6.
 
52) 中村丁次. "臨床検査". 臨床栄養管理. 中村丁次ほか編. 第一出版, 1997, 103-8.
 
53) 加藤明彦. 生化学的指標による透析患者の栄養評価. 臨牀透析. 20, 2004, 1499-505.
 
54) Kalantar-Zadeh, K. Revisiting mortality predictability of serum albumin in the dialysis population : time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 20, 2005, 1880-8.
PubMed
55) Shinzato, T. New method to calculate creatinine generation rate using pre- and postdialysis creatinine consentrations. Artif Organs. 21, 1997, 864-72.
 
56) 山口百子. "食事調査". 臨床栄養管理. 中村丁次ほか編. 第一出版, 1997, 84-92.
 
57) 金澤良枝. 透析患者の食事摂取量の評価法. 臨牀透析. 20, 2004, 1543-8.
 
58) Lowrie, EG. Effects of the hemodialysis prescription of patient morbidity : Report from the National Cooperative Dialysis Study. N Engl J Med. 305, 1981, 1176-81.
PubMed
59) Gotch, FA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int. 28, 1985, 526-34.
PubMed
60) 木村玄次郎. 透析患者における食事摂取量の定量的算出. 腎と透析. 19, 1985, 605-10.
 
61) 木村玄次郎. "食事療法と栄養状態の評価". ワンポイントノートで学ぶ透析療法の基本. 東京医学社, 1993, 61-70.
 
62) Shinzato, T. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentration. Nephron. 67, 1994, 280-90.
 
63) Kopple, JD. A proposed glossary for dialysis kinetics. Am J Kidney Dis. 26, 1995, 963-81.
PubMed
64) 木村玄次郎. "透析療法への定量的アプローチ". 腎不全. 阿部正和ほか編. 金原出版, 1986, 254-68.
 
65) 木村玄次郎. "透析療法のコントロール基準". ワンポイントノートで学ぶ透析療法の基本. 東京医学社, 1993, 13-39.
 
66) Lopez-Gomez, JM. Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. Kidney Int. 67 (suppl 93), 2005, s63-s68.
 
67) Testa, A. The other side of coin : Interdialytic weight gain as an index of good nutrition. Am J Kidney Dis. 31, 1998, 830-4.
PubMed
68) 日本透析医学会. わが国の慢性透析療法の現況 (2000年12月31日現在). 2001, 499-505.
 
69) Kopple, J. Body weight for height relationships predict mortality in maintenance hemodialysis patients. Kidney Int. 56, 1999, 1136-46.
PubMed
70) Wolf, R. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis. 35, 2000, 80-8.
 
71) Johansen, KL. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr. 80, 2004, 324-32.
PubMed
72) Lowrie, EG. Body size, dialysis dose and death risk relationships among hemodialysis patients. Kidney Int. 62, 2002, 1891-7.
PubMed
73) Sarkar, SR. Metabolic consequences of body size and body composition in hemodialysis patients. Kidney Int. 70, 2006, 1832-9.
PubMed
74) Kotanko, P. The impact of visceral mass on survival in chronic hemodialysis patients. Int J Artif Organs. 30, 2007, 993-9.
PubMed
75) Kotanko, P. Size matters : Body composition and outcomes in maintenance hemodialysis patients. Blood Purif. 25, 2007, 27-30.
PubMed
76) Kakiya, R. Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int. 70, 2006, 549-56.
PubMed
77) Shoji, T. Body fat measurement in chronic kidney disease : implications in research and clinical practice. Curr Opin Nephrol Hypertens. 16, 2007, 572-6.
PubMed
78) Kato, A. Influence of body composition on 5 year mortality in patients on regular haemodialysis. Nephrol Dial Transplant. 18, 2003, 333-40.
PubMed
79) Kalantar-Zadeh, K. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 46, 2005, 489-500.
PubMed
80) Kalantar-Zadeh, K. Associations of body fat and its change over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr. 83, 2006, 202-10.
PubMed
81) Ikizler, TA. Resolved : Being fat is good for dialysis patients : The Godzilla effect. J Am Soc Nephrol. 19, 2008, 1059-64.
 
82) Wong, J. Survival advantage in asian American ESRD patients. Kidney Int. 55, 1999, 2515-23.
PubMed
83) Wolfson, M. Intradialytic parenteral nutrition : A useful therapy? Nutr Clin Pract. 11, 1996, 5-11.
PubMed
84) 望月隆弘. るいそうに対する薬物療法. 臨牀透析. 16, 2000, 791-7.
 
85) Pupim, LB. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest. 110, 2002, 483-92.
PubMed
86) Ikizler, TA. Protein and energy : Recommended intake and nutrient supplementation in chronic dialysis patients. Semin Dial. 17, 2004, 471-8.
PubMed
87) 椿原美治. 慢性血液透析患者における蛋白・アミノ酸代謝異常と必須アミノ酸療法の検討. 日腎会誌. 24, 1982, 1127-36.
 
88) Caglar, K. Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int. 62, 2002, 1054-9.
PubMed
89) Kalantar-Zadeh, K. Diets and enteral supplement for improving outcomes in chronic kidney disease. Nat Rev Nephrol. 7, 2011, 369-84.
PubMed
90) Kshirsagar, AV. Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int. 75, 2009, 746-51.
PubMed
91) Akar, H. Systemic consequences of poor oral health in chronic kidney disease patients. Clin J Am Soc Nephrol. 6, 2011, 218-26.
PubMed
92) Craig, RG. Periodontal diseases and systemic inflammatiom. Semin Dial. 26, 2013, 23-8.
 
93) Kouidi, E. Exercise training in dialysis patients : Why, when, and how? Artif Organs. 26, 2002, 1009-13.
PubMed
94) Johansen, KL. Exercise in the end-stage renal disease population. J Am Soc Nephrol. 18, 2007, 1845-54.
PubMed
95) Vaithilingam, I. Time and exercise improve phosphate removal in hemodialysis patients. Am J Kidney Dis. 43, 2004, 85-9.
PubMed
96) Kong, CH. The effect of exercise during haemodialysis on solute removal. Nephrol Dial Transplant. 14, 1999, 2927-31.
PubMed
97) Pupim, LB. Exercise augments the acute anabolic effects of intradialytic parenteral nutrition in chronic hemodialysis patients. Am J Physiol Endcrinol Metab. 286, 2004, e589-e597.
 

6章 バスキュラーアクセスに気を配る

P.207 掲載の参考文献
1) 日本透析医学会. 2011年版 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌. 44, 2011, 855-937.
 
2) Kronung, G. Plastic deformation of Cimino fistula by repeating puncture. Dial Transplant. 13, 1984, 635-8.
 
3) Twardowski, ZJ. Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment by repeated dialysis. Dial Transplant. 8, 1979, 978-80.
 
4) Twardowski, ZJ. Constant site (Buttonhole) method of needle insertion for hemodialysis. Dial Transplant 24, 1995, 559-76.
 
5) Verhallen, AM. Cannulating in haemodialysis : rope-ladder of buttonhole technique? Nephrol Dial Transplant. 22, 2007, 2601-4.
PubMed
6) van Loon, MM. Buttonhole needling of haemodialysis arteriovenous fistulae results in less complications and interventions compared to the ropre-ladder technique. Nephrol Dial Transplant. 25, 2010, 225-30.
 
7) 當間茂樹. Buttonhole穿刺のための時間節約型固定穿刺ルート作成法. 透析会誌. 33, 2000, 1431-5.
 
8) MacRae, JM. A randomized trial comparing buttonhole with rope ladder needling in conventional hemodialysis patients. Clin J Am Soc Nephrol. 7, 2012, 1632-8.
PubMed
9) Labriola, L. Infectious complication following conversion to buttonhole cannulation of native arteriovenous fistulas : A quality improvement report. Am J Kidney Dis. 57, 2011, 442-8.
PubMed
10) 多川斉. ブラッドアクセスと心機能. 臨牀透析. 12, 1996, 943-51.
 

7章 患者さん本位の至適透析をめざして

P.229 掲載の参考文献
1) 日本透析医学会. 2011年版 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌. 44, 2011, 855-937.
 
2) NKF-DOQI Vascular access work group. NKF-DOQI clinical practice guideline for vascular access. Am J Kidney Dis. 30, 1997, 150-91.
 
3) Tordoir, J. EBPG on vascular access. Nephrol Dial Transplant. 22 (suppl 2), 2007, ii88-ii117.
 
4) Chandna, SM. Residual renal function : Consideration on its importance and preservation in dialysis patients. Semin Dial. 17, 2004, 196-201.
PubMed
5) Canaud, B. Residual renal function and dialysis modality, Is it really beneficial to preserve residual renal function in dialysis patients? Nephrol. 11, 2006, 292-6.
 
6) Wang, AY. The importance of residual renal function in dialysis patients. Kidney Int. 69, 2006, 1726-32.
PubMed
7) 社会保険研究所編. "J038人工腎臓". 医科点数表の解釈. 第35版. 社会保険研究所, 2008, 468-71.
 
8) 日本透析医学会. 維持血液透析ガイドライン : 血液透析処方. 透析会誌. 46, 2013, 587-632.
 
9) Scribner, BH. Why thrice weekly dialysis? Hemodial Int. 8, 2004, 188-92.
PubMed
10) 鈴木一之. 至適透析・適正透析に関する私見. 透析会誌. 30, 1997, 1099-100. (letter)
 
11) Pauly, RP. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant. 24, 2009, 2915-9.
PubMed
12) 川西秀樹. 至適で自由な透析医療を求めて. 臨牀透析. 17, 2001, 1543-4.
 
13) Scribner, BH. The hemodialysis product (HDP) : A better index of dialysis adequacy than Kt/V. Dial Transplant. 31, 2002, 13-5.
 

文献リスト

P.271 掲載の参考文献
1) 竹沢真吾編. 血液透析スタッフのための新しいハイパフォーマンスダイアライザー. 東京医学社, 1998, 317p.
 
2) 竹沢真吾. 血液透析とエンドトキシン. 東京医学社, 2002, 126p.
 
3) 竹沢真吾. 透析液のバイ菌がよくわかる本. 東京医学社, 2008, 226p.
 
4) 堀澤毅雄. 透析者と家族が元気になる本. サンマーク出版, 2004, 223p.
 
5) 斎藤明ほか編. 血液浄化療法の指針 : 新しい方向性. 日本メディカルセンター, 1997, 183p.
 
6) 金成泰編. 実践的アプローチ透析液水質管理＆オンラインHDF. メディカルレビュー社, 1996, 297p.
 
7) 日本HDF研究会編. HDF療法ハンドブック. 南江堂, 2000, 207p.
 
8) 金田浩. 続21世紀の慢性透析治療法と革命しよう : 長時間透析と限定自由食のすすめ. 東京医学社, 2005, 106p.
 
9) 木村玄次郎. ワンポイントノートで学ぶ透析療法の基本. 東京医学社, 1993, 120p.
 
10) 中井洋. ケアに生かす「透析学」入門. メディカ出版, 2001, 230p.
 
11) 香川靖雄ほか. ナースのための生化学・栄養学. 改訂4版. 南山堂, 2006, 274p.
 
12) 大平整爾ほか. バスキュラーアクセス : その作製・維持・修復の実際. 中外医学社, 2007, 211p.
 
13) 太田和夫. シャント : 使用法と合併症の対策. 東京医学社, 1993, 179p.
 

書評

最近チェックした商品履歴

Loading...